Adaptimmune announces New Board Appointments as clinical programmes get underway. Please click here for Press Release

Adaptimmune announced today that it has opened a Pilot, open‐label clinical trial in synovial sarcoma at the National Cancer Institute (NCI), Bethesda, Maryland. Please click here for Press Release

Adaptimmune announced today that it has opened a Phase I/II, two cohort, open label clinical trial in metastatic melanoma at Washington University, St. Louis, Missouri.  Please click here for Press Release

Adaptimmune has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy. Please click here for Press Release

Adaptimmune Limited today announced that it has launched a US subsidiary, Adaptimmune LLC, located in Philadelphia, and appointed Dr Gwen Binder-Scholl as Vice President of Operations of the new company. Please click on this link to download the full Press Release      

Researchers at Adaptimmune and the University of  Pennsylvania announce the approval of an IND and opening for enrolment of the first ever study using engineered T cells to treat HIV

October 7th, 2009 Oxford, UK and Philadelphia, PA: 7 October 2009. Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine announce the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients’ cells carrying an [...]

Click below to download Press Release :- Adaptimmune Ltd Press Release – 09 Nov 2008

Adaptimmune was officially founded on the 1st July 2008 with the remit of advancing the use of engineered T cell receptors in adoptive T cell therapy.